MarginsXMarginsX
Home › Markets › Health Care › ARVN

Arvinas Inc. (ARVN)

ARVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.77
-0.73% on the day
Market cap
$443.3M
Small cap
Revenue · 2025
$262.6M
-0.3% on 2024
Net income · 2025
-$80.8M
-30.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/0001628280-26-011226-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerARVN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001655759
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$262.6M
Net income-$80.8M
Operating income-$118.5M
Net margin-30.8%
Operating margin-45.1%
Revenue growth-0.3%
Cash$142.9M
Total assets$717.9M
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
6.7 months
$88.0M cash at September 30, 2026
Share count, 1 year
+2.0%
2025-10-31 to 2026-10-30 · +19.0% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$1.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$88.0M cash; operating cash flow -$39.6M a quarter.Report 2026-09-30
Shares outstanding65,485,006 (2026-10-30); 64,224,294 a year earlier; 55,025,504 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $268K, sold $1.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$500K-$53.9M-$10.4M$88.0M$400K$275.3M10-Q 2026-11-03
Q2 2026
2026-06-30
$249.7M$169.4M-$48.3M$94.3M$500K$316.7M10-Q 2026-08-04
Q1 2026
2026-03-31
$15.6M-$57.6M-$69.2M$87.3M$500K$89.4M10-Q 2026-05-11
Q4 2025
2025-12-31
$9.5M-$67.4M-$30.4M$142.9M$600K$262.6M10-K 2026-02-24
Q3 2025
2025-09-30
$41.9M-$35.1M-$59.1M$101.5M$600K$312.3M10-Q 2025-11-05
Q2 2025
2025-06-30
$22.4M-$61.2M-$95.4M$114.9M$700K$372.8M10-Q 2025-08-06
Q1 2025
2025-03-31
$188.8M$82.9M-$88.9M$81.0M$700K$426.9M10-Q 2025-05-01
Q4 2024
2024-12-31
$59.2M-$45.1M-$84.1M$100.5M$800K$263.4M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-03
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 605 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.4%
1 month-0.3%
3 months-24.3%
Year to date-42.5%
1 year-32.6%
From 52-week high-50.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
EOLSEvolus Inc.$6.63-4.74%$438.8M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier